Cantel Medical Appoints New Director
May 27 2008 - 7:30AM
Business Wire
CANTEL MEDICAL CORP. (NYSE:CMN) announced the appointment of George
L. Fotiades to fill the vacancy created by the resignation of R.
Scott Jones as a director on April 23, 2008. Mr. Fotiades is
Chairman of the healthcare investment practice of Diamond Castle
Holdings LLC, a private equity investment firm. Prior to joining
Diamond Castle in 2007, Mr. Fotiades was President and Chief
Operating Officer of Cardinal Health, Inc., a leading provider of
products and services supporting the healthcare industry. Prior to
that position, he served as President and CEO of Cardinal's
Pharmaceutical Technologies and Services segment, the largest
provider of contract manufacturing and packaging services to the
pharmaceutical industry. Previously, he served in a variety of
executive roles including President of Warner-Lambert's consumer
healthcare business and senior positions at Bristol-Myers Squibb,
Wyeth and Procter & Gamble. Mr. Fotiades is non-executive
Chairman of Catalent Pharma Solutions and a Director of ProLogis
(NYSE:PLD) and The Alberto-Culver Company (NYSE:ACV). He holds an
A.B. from Amherst College and an M.M. from the Kellogg School of
Management at Northwestern University. Charles M. Diker, Cantel�s
Chairman, commented, �George�s experience in the healthcare
industry � both in operations and finance � make him a valuable
addition to the Board.� Cantel Medical Corp. is a leading provider
of infection prevention and control products in the healthcare
market. Our products include specialized medical device
reprocessing systems for renal dialysis and endoscopy, dialysate
concentrates and other dialysis supplies, disposable infection
control products primarily for the dental industry, water
purification equipment, sterilants, disinfectants and cleaners,
hollow fiber membrane filtration and separation products for
medical and non-medical applications, and specialty packaging for
infectious and biological specimens. We also provide technical
maintenance for our products and offer compliance training services
for the transport of infectious and biological specimens. For
further information, visit the Cantel website at
www.cantelmedical.com. This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements involve a number of risks and
uncertainties, including, without limitation, the risks detailed in
Cantel's filings and reports with the Securities and Exchange
Commission. Such forward-looking statements are only predictions,
and actual events or results may differ materially from those
projected or anticipated.
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024